Cytosurge/ Exaddon AG
cytosurge exaddon
Swiss nanotechnology company Cytosurge has announced its 3D printing business unit has been spun out and will continue operations under the Exaddon brand name.
Exaddon AG will oversee all of Cytosurge’s existing additive manufacturing projects and continue to serve its 3D printing clients. The new company will focus on the additive manufacture of micro metal parts for industry and academia, with Edgar Hepp, who has worked at the original Cytosurge business unit since it was established two and a half years ago, heading the new venture.
Cytosurge’s 3D printing business unit was deployed to explore the application of the FluidFM technology – originally developed at ETH Zurich ten years ago – to micro additive manufacturing. Since, the 3D printing business unit has successfully collaborated with clients in the pharmaceutical industry and in the field of bioscience research. Now, Cytosurge believes FluidFM micro 3D printing is ready for commercialisation, and so has spun out Hepp and his team into Exaddon AG.
Exaddon and Cytosurge will continue to work closely together, collaborating on selected strategic projects, but Exaddon will also begin to broaden its horizons and leverage its technology for other target markets.
“The original decision to develop this revolutionary additive manufacturing technology and to develop this new application of FluidFM technology has definitely paid off for us,” commented Dr. Pascal Behr, CEO of Cytosurge. “Given the unique nature of the additive manufacturing business and specific requirements of our key target markets, such as the semiconductor industry, we are convinced that an independent company can realise the high growth opportunities in this emerging market much better if it can focus entirely on this key goal. We are very proud to announce the establishment of Exaddon AG for this purpose and I am convinced that Edgar and his team will thrive.”
“We have developed a ground-breaking manufacturing technology and have brought it to market maturity,” added CEO Hepp. “It enables our clients to additively manufacture high-end products at an unprecedented level. Exaddon AG is now responsible for all Cytosurge AG projects related to additive manufacturing and will continue to manage and develop them.”
